What's on this Page
What is Risankizumab
Risankizumab, an interleukin-23 antagonist, is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Treatment with risankizumab may increase the risk of infections. Caution is advised when administering the drug to patients with a history of chronic or recurrent infections.
Prior to initiating therapy, all potential drug recipients must be evaluated for tuberculosis (TB) infections.
Do not administer risankizumab to patients with active TB infection; patients with latent TB should initiate treatment before receiving.
Brand Name
Skyrizi
Indications
- psoriasis
For the treatment of moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy
Side Effects
- antibody formation
- asthenia
- bleeding
- edema
- erythema
- fatigue
- folliculitis
- headache
- hematoma
- infection
- injection site reaction
- osteomyelitis
- pharyngitis
- pruritus
- rhinitis
- sinusitis
- urticaria
Monitoring Parameters
- tuberculin skin test
Contraindications
- breast-feeding
- immunosuppression
- infection
- pregnancy
- tuberculosis
- vaccination
Interactions
- Bacillus Calmette-Guerin Vaccine, BCG
- Influenza Virus Vaccine
- Intranasal Influenza Vaccine
- Live Vaccines
- Measles Virus; Mumps Virus; Rubella Virus; Varicella Virus Vaccine, Live
- Measles/Mumps/Rubella Vaccines, MMR
- Rotavirus Vaccine
- Rubella Virus Vaccine Live
- Smallpox and Monkeypox Vaccine, Live, Nonreplicating
- Smallpox Vaccine, Vaccinia Vaccine
- Typhoid Vaccine
- Varicella-Zoster Virus Vaccine, Live
- Yellow Fever Vaccine, Live
